Rinvatercept
AssetAlso KER-065
Modified activin receptor type II ligand-trap protein
- Stage
- Phase 2
- Modality
- Protein or enzyme
- Target
- ACVR2A
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Duchenne muscular dystrophy
Phase 2, ir.kerostx.com, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets2
- Competitors2
Every asset’s record: target, stage, trials and the evidence behind it.